Authors
Yun Bao, Jing Quan, Pengyin Zhang, Xue Yang, Xiaobo Hu
Published in
PloS one. Volume 21. Issue 11. Pages e0362593. Epub Nov 16, 2026.
Abstract
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most prevalent enzymatic disorder of red blood cells. Early identification of at‑risk individuals through genetic testing facilitates the implementation of targeted preventive measures to reduce disease burden. However, the accuracy and reliability of molecular testing across clinical laboratories have not been systematically established. This pioneering study assessed current laboratory performance in analyzing and reporting G6PD-related variants through an annual external quality assessment (EQA) program. A panel of five dried blood spots (DBS) mimicking samples was prepared from distinct cell lines and distributed to participants. The sample panel contained four positive samples carrying G6PD pathogenic variants, including hemizygous, heterozygous, and compound heterozygous genotypes, and one negative sample. Of 23 participating laboratories, only 14 (60.87%) achieved full marks. Although all participants successfully detected pathogenic mutations, 49 variant reporting errors were identified and categorized into four types. Most laboratories yielded satisfactory results; however, improvements are needed in variant description and result reporting. These findings highlight the necessity of continued education on international reporting standards and robust quality assurance to ensure accurate, consistent genetic variants interpretation across laboratories.
PMID:
43038287
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 13
- Comments 0